Top

Supportive Care in Cancer

Published in:

Open Access 01-09-2017 | Review Article

Effects of resistance exercise in prostate cancer patients: a meta-analysis

Authors: M. Keilani, T. Hasenoehrl, L. Baumann, R. Ristl, M. Schwarz, M. Marhold, T. Sedghi Komandj, R. Crevenna

Published in: Supportive Care in Cancer | Issue 9/2017

Abstract

Purpose

The aim of the present meta-analysis was to quantify effects of resistance exercise (RE) on physical performance and function, body composition, health-related quality of life (HRQoL), and fatigue in patients with prostate cancer.

Methods

Trial data were obtained from the databases PubMed, MEDLINE, EMBASE, SCOPUS, and the Cochrane Library as of inception to 31st of December 2016. Thirty-two trials with 1199 patients were included. Results that were measured by using the same assessment method in five or more of the original studies were pooled in a meta-analysis.

Results

Pooled studies showed significant improvements of muscular strength in the upper and lower body (95% CI [2.52, 7.97] kg; p < 0.001 and 95% CI [10.51, 45.88] kg; p = 0.008, respectively) after RE. Furthermore, significant improvements were seen for body composition (body fat percentage 95% CI [−0.79, −0.53] %; p < 0.001; lean body mass 95% CI [0.15, 1.84] %; p = 0.028; trunk fat mass 95% CI [−0.73, −0.08] kg; p = 0.024). Additionally, the improvement of the 400-m walk time was significant (95% CI [−21.55, −14.65] s; p < 0.001). Concerning fatigue and HRQoL, there were not sufficient data for analysis.

Conclusions

RE seems to be a promising approach in order to counteract loss of muscle mass, muscle strength, and physical performance in patients suffering from prostate cancer and its treatment-related side effects. RE should play part in interdisciplinary cancer rehabilitation and care of this patient group. Nevertheless, further research should investigate RE further to determine which protocols are the most pragmatic, yet yielding best patient outcomes.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. doi:10.1002/ijc.29210 CrossRefPubMed

Statistik Austria (2016) Prostata (C61) - Relative Überlebensraten in Österreich nach Geschlecht (1987–2014). 2016

Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, Drake CG, de Bono JS (2016) Prostate cancer. Lancet 387:70–82. doi:10.1016/S0140-6736(14)61947-4 CrossRefPubMed

Rhee H, Gunter JH, Heathcote P, Ho K, Stricker P, Corcoran NM, Nelson CC (2015) Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int 115:3–13. doi:10.1111/bju.12964 CrossRefPubMed

Llorente MD, Burke M, Gregory GR, Bosworth HB, Grambow SC, Horner RD, Golden A, Olsen EJ (2005) Prostate cancer: a significant risk factor for late-life suicide. Am J Geriatr Psychiatry 13:195–201. doi:10.1176/appi.ajgp.13.3.195 CrossRefPubMed

Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson C, Watson RB, Gardiner RA (2002) Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90:427–432. doi:10.1046/j.1464-410X.2002.02917.x CrossRefPubMed

Walker LM, Tran S, Robinson JW (2013) Luteinizing hormone-releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer 11:375–384. doi:10.1016/j.clgc.2013.05.004 CrossRefPubMed

Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson CE, Watson RB, Gardiner RA (2004) Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 93:975–979. doi:10.1111/j.1464-410X.2004.04763.x CrossRefPubMed

Cormie P, Oliffe JL, Wootten AC, Galvão DA, Newton RU, Chambers SK (2016) Improving psychosocial health in men with prostate cancer through an intervention that reinforces masculine values—exercise. Psychooncology 25:232–235. doi:10.1002/pon.3867 CrossRefPubMed

10.

Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2013) Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 64:159–166. doi:10.1016/j.eururo.2012.04.035 CrossRefPubMed

11.

Levine GN, D’Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society and the AUA (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121:833–840. doi:10.1161/CIRCULATIONAHA.109.192695 CrossRefPubMedPubMedCentral

12.

Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R (2008) Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 102:44–47. doi:10.1111/j.1464-410X.2008.07539.x CrossRefPubMed

13.

Galvão DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU (2009) Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 12:198–203. doi:10.1038/pcan.2008.51 CrossRefPubMed

14.

Smith MR, Lee H, Fallon MA, Nathan DM (2008) Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 71:318–322. doi:10.1016/j.urology.2007.08.035 CrossRefPubMedPubMedCentral

15.

Hamilton EJ, Ghasem-Zadeh A, Gianatti E, Lim-Joon D, Bolton D, Zebaze R, Seeman E, Zajac JD, Grossmann M (2010) Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab 95:E456–E463. doi:10.1210/jc.2010-0902 CrossRefPubMed

16.

Beebe-Dimmer JL, Cetin K, Shahinian V, Morgenstern H, Yee C, Schwartz KL, Acquavella J (2012) Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States. Pharmacoepidemiol Drug Saf 21:70–78. doi:10.1002/pds.2258 CrossRefPubMed

17.

Storer TW, Miciek R, Travison TG (2012) Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl 14:204–221. doi:10.1038/aja.2011.104 CrossRefPubMedPubMedCentral

18.

Hasenoehrl T, Keilani M, Sedghi Komanadj T, Mickel M, Margreiter M, Marhold M, Crevenna R (2015) The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review. Support Care Cancer 23:2479–2497. doi:10.1007/s00520-015-2782-x CrossRefPubMed

19.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev CD006019. doi: 10.1002/14651858.CD006019.pub2

20.

Higano CS (2012) Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. J Clin Oncol 30:3720–3725. doi:10.1200/JCO.2012.41.8509 CrossRefPubMed

21.

Harrington JM, Schwenke DC, Epstein DR, Bailey DE (2014) Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. Oncol Nurs Forum 41:21–29. doi:10.1188/14.ONF.21-29 CrossRefPubMed

22.

Bolla M, de Reijke TM, Van Tienhoven G, den Bergh ACM V, Oddens J, Poortmans PMP, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L, EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527. doi:10.1056/NEJMoa0810095 CrossRefPubMed

23.

Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU, Radiation Therapy Oncology Group (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21:3972–3978. doi:10.1200/JCO.2003.11.023 CrossRefPubMed

24.

Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D, Carroll PR (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Urol Oncol Semin Orig Investig 23:462–463. doi:10.1016/j.urolonc.2005.08.015

25.

Wilke DR, Krahn M, Tomlinson G, Bezjak A, Rutledge R, Warde P (2010) Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy. Cancer 116:1909–1917. doi:10.1002/cncr.24905 CrossRefPubMed

26.

Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S (2006) Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 18:494–498. doi:10.1038/sj.ijir.3901471 CrossRefPubMed

27.

Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU (2009) Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure. Prostate Cancer Prostatic Dis 12:233–240. doi:10.1038/pcan.2009.12 CrossRefPubMed

28.

Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C (2003) Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 104:195–201. doi:10.1042/CS20020209 CrossRef

29.

Collier A, Ghosh S, McGlynn B, Hollins G (2012) Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease. Am J Clin Oncol 35:504–509. doi:10.1097/COC.0b013e318201a406 CrossRefPubMed

30.

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110:1493–1500. doi:10.1002/cncr.22933 CrossRefPubMed

31.

Nguyen PL, Chen M-H, Beckman JA, Beard CJ, Martin NE, Choueiri TK, Hu JC, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D’Amico AV, Ennis RD (2012) Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys 82:1411–1416. doi:10.1016/j.ijrobp.2011.04.067 CrossRefPubMed

32.

Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164. doi:10.1056/NEJMoa041943 CrossRefPubMed

33.

D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420–2425. doi:10.1200/JCO.2006.09.3369 CrossRefPubMed

34.

Strasser B, Steindorf K, Wiskemann J, Ulrich CM (2013) Impact of resistance training in cancer survivors: a meta-analysis. Med Sci Sports Exerc 45:2080–2090. doi:10.1249/MSS.0b013e31829a3b63 CrossRefPubMed

35.

Lemes IR, Ferreira PH, Linares SN, Machado AF, Pastre CM, Netto JJ (2016) Resistance training reduces systolic blood pressure in metabolic syndrome: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med 50:1–6. doi:10.1136/bjsports-2015-094715 CrossRef

36.

Ricci-Vitor AL, Bonfim R, Fosco LC, Bertolini GN, Ramos EMC, Ramos D, Pastre CM, Godoy M, Vanderlei LCM (2013) Influence of the resistance training on heart rate variability, functional capacity and muscle strength in the chronic obstructive pulmonary disease. Eur J Phys Rehabil Med 49:793–801PubMed

37.

Smith MR (2003) Changes in body composition during hormonal therapy for prostate cancer. Clin Prostate Cancer 2:18–21CrossRefPubMed

38.

Strasser B, Arvandi M, Siebert U (2012) Resistance training, visceral obesity and inflammatory response: a review of the evidence. Obes Rev 13:578–591. doi:10.1111/j.1467-789X.2012.00988.x CrossRefPubMed

39.

Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM (2011) Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Cancer Epidemiol Biomark Prev 20:647–657. doi:10.1158/1055-9965.EPI-10-1143 CrossRef

40.

Bourke L, Gilbert S, Hooper R, Steed LA, Joshi M, Catto JWF, Saxton JM, Rosario DJ (2014) Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 65:865–872. doi:10.1016/j.eururo.2013.09.040 CrossRefPubMed

41.

Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvão DA (2013) Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis 16:328–335. doi:10.1038/pcan.2013.22 CrossRefPubMed

42.

Cormie P, Galvão DA, Spry N, Joseph D, Chee R, Taaffe DR, Chambers SK, Newton RU (2015) Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int 115:256–266. doi:10.1111/bju.12646 CrossRefPubMed

43.

Galvão DA, Nosaka K, Taffee DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU (2006) Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38:2045–2052. doi:10.1249/01.mss.0000233803.48691.8b CrossRefPubMed

44.

Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28:340–347. doi:10.1200/JCO.2009.23.2488 CrossRefPubMed

45.

Galvão DA, Spry N, Denham J, Taaffe DR, Cormie P, Joseph D, Lamb DS, Chambers SK, Newton RU (2014) A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 radar. Eur Urol 65:856–864. doi:10.1016/j.eururo.2013.09.041 CrossRefPubMed

46.

Hanson ED, Sheaff AK, Sood S, Ma L, Francis JD, Goldberg AP, Hurley BF (2013) Strength training induces muscle hypertrophy and functional gains in black prostate cancer patients despite androgen deprivation therapy. J Gerontol Ser A Biol Sci Med Sci 68:490–498. doi:10.1093/gerona/gls206 CrossRef

47.

Mina DS, Alibhai SMH, Matthew AG, Guglietti CL, Pirbaglou M, Trachtenberg J, Ritvo P (2013) A randomized trial of aerobic versus resistance exercise in prostate cancer survivors. J Aging Phys Act 21:455–478CrossRef

48.

Park SW, Kim TN, Nam JK, Ha HK, Shin DG, Lee W, Kim MS, Chung MK (2012) Recovery of overall exercise ability, quality of life, and continence after 12-week combined exercise intervention in elderly patients who underwent radical prostatectomy: a randomized controlled study. Urology 80:299–305. doi:10.1016/j.urology.2011.12.060 CrossRefPubMed

49.

Segal RJ (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21:1653–1659. doi:10.1200/JCO.2003.09.534 CrossRefPubMed

50.

Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D’Angelo ME (2009) Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 27:344–351. doi:10.1200/JCO.2007.15.4963 CrossRefPubMed

51.

Winters-Stone MK, Dobek CJ, Bennett AJ, Maddalozzo FG, Ryan WC, Beer MT (2014) Skeletal response to resistance and impact training in prostate cancer survivors. Med Sci Sports Exerc 46:1482–1488. doi:10.1249/MSS.0000000000000265 CrossRefPubMedPubMedCentral

52.

Livingston PM, Craike MJ, Salmon J, Courneya KS, Gaskin CJ, Fraser SF, Mohebbi M, Broadbent S, Botti M, Kent B (2015) Effects of a clinician referral and exercise program for men who have completed active treatment for prostate cancer: a multicenter cluster randomized controlled trial (ENGAGE). Cancer 121:2646–2654. doi:10.1002/cncr.29385 CrossRefPubMedPubMedCentral

53.

Nilsen TS, Raastad T, Skovlund E, Courneya KS, Langberg CW, Lilleby W, Fosså SD, Thorsen L (2015) Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy. Acta Oncol (Madr) 54:1805–1813. doi:10.3109/0284186X.2015.1037008 CrossRef

54.

Winters-Stone KM, Lyons KS, Dobek J, Dieckmann NF, Bennett JA, Nail L, Beer TM (2016) Benefits of partnered strength training for prostate cancer survivors and spouses: results from a randomized controlled trial of the Exercising Together project. J Cancer Surviv 10:633–644 1–12. doi:10.1007/s11764-015-0509-0 CrossRefPubMed

55.

Hojan K, Kwiatkowska-Borowczyk E, Leporowska E, Gorecki M, Ozga-Majchrzak O, Milecki TMP (2016) Physical exercise for functional capacity, blood immune function, fatigue and quality of life in high-risk prostate cancer patients during radiotherapy. A prospective, randomised clinical study. Eur J Phys Rehabil Med 52:489–501PubMed

56.

Alberga AS, Segal RJ, Reid RD, Scott CG, Sigal RJ, Khandwala F, Jaffey J, Wells GA, Kenny GP (2012) Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer. Support Care Cancer 20:971–981. doi:10.1007/s00520-011-1169-x CrossRefPubMed

57.

Buffart LM, Galvão DA, Chinapaw MJ, Brug J, Taaffe DR, Spry N, Joseph D, Newton RU (2014) Mediators of the resistance and aerobic exercise intervention effect on physical and general health in men undergoing androgen deprivation therapy for prostate cancer. Cancer 120:294–301. doi:10.1002/cncr.28396 CrossRefPubMed

58.

Cormie P, Newton RU, Taaffe DR, Spry N, Joseph D, Akhlil Hamid M, Galvão DA (2013) Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial. Prostate Cancer Prostatic Dis 16:170–175. doi:10.1038/pcan.2012.52 CrossRefPubMed

59.

Courneya KS, Segal RJ, Reid RD, Jones LW, Malone SC, Venner PM, Parliament MB, Scott CG, Quinney HA, Wells GA (2004) Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivors. J Clin Epidemiol 57:571–579. doi:10.1016/j.jclinepi.2003.11.010 CrossRefPubMed

60.

Galvão DA, Nosaka K, Taaffe DR, Peake J, Spry N, Suzuki K, Yamaya K, McGuigan MR, Kristjanson LJ, Newton RU (2008) Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis 11:160–165. doi:10.1038/sj.pcan.4500991 CrossRefPubMed

61.

Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU (2011) Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response. J Urol 186:1291–1297. doi:10.1016/j.juro.2011.05.055 CrossRefPubMed

62.

Mina DS, Connor MK, Alibhai SMH, Toren P, Guglietti C, Matthew AG, Trachtenberg J, Ritvo P (2013) Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: a randomized study. Can Urol Assoc J 7:E692–E698. doi:10.5489/cuaj.235 CrossRefPubMedCentral

63.

Winters-Stone KM, Dobek JC, Bennett JA, Dieckmann NF, Maddalozzo GF, Ryan CW, Beer TM (2014) Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. Arch Phys Med Rehabil 96:7–14. doi:10.1016/j.apmr.2014.08.010 CrossRefPubMedPubMedCentral

64.

Gaskin CJ, Fraser SF, Owen PJ, Craike M, Orellana L, Livingston PM (2016) Fitness outcomes from a randomised controlled trial of exercise training for men with prostate cancer: the ENGAGE study. J Cancer Surviv. doi:10.1007/s11764-016-0543-6

65.

Nilsen TS, Thorsen L, Fosså SD, Wiig M, Kirkegaard C, Skovlund E, Benestad HB, Raastad T (2015) Effects of strength training on muscle cellular outcomes in prostate cancer patients on androgen deprivation therapy. Scand J Med Sci Sports 26:1026–1035. doi:10.1111/sms.12543 CrossRefPubMed

66.

Nilsen TS, Thorsen L, Kirkegaard C, Ugelstad I, Fosså SD, Raastad T (2016) The effect of strength training on muscle cellular stress in prostate cancer patients on ADT. Endocr Connect 5:74–82. doi:10.1530/EC-15-0120 PubMedPubMedCentral

67.

Buffart LM, Newton RU, Chinapaw MJ, Taaffe DR, Spry NA, Denham JW, Joseph DJ, Lamb DS, Brug J, Galvao DA (2015) The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer. Cancer 121:2821–2830. doi:10.1002/cncr.29406 CrossRefPubMed

68.

Gilbert SE, Tew GA, Fairhurst C, Bourke L, Saxton JM, Winter EM, Rosario DJ (2016) Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer. Br J Cancer 114:401–408. doi:10.1038/bjc.2015.479 CrossRefPubMedPubMedCentral

69.

Lyons KS, Winters-Stone KM, Bennett JA, Beer TM (2016) The effects of partnered exercise on physical intimacy in couples coping with prostate cancer. Health Psychol 35:509–513. doi:10.1037/hea0000287 CrossRefPubMed

70.

Winters-Stone KM, Dieckmann N, Maddalozzo GF, Bennett JA, Ryan CW, Beer TM (2015) Resistance exercise reduces body fat and insulin during androgen-deprivation therapy for prostate cancer. Oncol Nurs Forum 42:348–356. doi:10.1188/15.ONF.348-356 CrossRefPubMed

71.

Gonnermann A, Framke T, Großhennig A, Koch A (2015) No solution yet for combining two independent studies in the presence of heterogeneity. Stat Med 34:2476–2480. doi:10.1002/sim.6473 CrossRefPubMedPubMedCentral

72.

Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36:1–48. doi:10.1103/PhysRevB.91.121108 CrossRef

73.

Cormie P, Pumpa K, Galvão DA, Turner E, Spry N, Saunders C, Zissiadis Y, Newton RU (2013) Is it safe and efficacious for women with lymphedema secondary to breast cancer to lift heavy weights during exercise: a randomised controlled trial. J Cancer Surviv 7:413–424. doi:10.1007/s11764-013-0284-8 CrossRefPubMed

74.

Muehlbauer T, Besemer C, Wehrle A, Gollhofer A, Granacher U (2012) Relationship between strength, power and balance performance in seniors. Gerontology 58:504–512. doi:10.1159/000341614 CrossRefPubMed

75.

Beauchamp MK, Jette AM, Ward RE, Kurlinski LA, Kiely D, Latham NK, Bean JF (2015) Predictive validity and responsiveness of patient-reported and performance-based measures of function in the Boston RISE Study. J Gerontol Ser A Biol Sci Med Sci 70:616–622. doi:10.1093/gerona/glu227 CrossRef

76.

Kwon S, Perera S, Pahor M, Katula JA, King AC, Groessl EJ, Studenski SA (2009) What is a meaningful change in physical performance? Findings from a clinical trial in older adults (The LIFE-P study). J Nutr Heal Aging 13:538–544. doi:10.1007/s12603-009-0104-z CrossRef

77.

Chipperfield K, Fletcher J, Millar J, Brooker J, Smith R, Frydenberg M, Burney S (2013) Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy. Psychooncology 22:2169–2176. doi:10.1002/pon.3269 CrossRefPubMed

78.

Gardner JR, Livingston PM, Fraser SF (2014) Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol 32:335–346. doi:10.1200/JCO.2013.49.5523 CrossRefPubMed

79.

Weaver KE, Forsythe LP, Reeve BB, Alfano CM, Rodriguez JL, Sabatino SA, Hawkins NA, Rowland JH (2012) Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomark Prev 21:2108–2117. doi:10.1158/1055-9965.EPI-12-0740 CrossRef

80.

Silver J, Baima J, Mayer R (2013) Impairment-driven cancer rehabilitation. Cancer J Clin 63:295–317. doi:10.3322/caac.21186 CrossRef

81.

Hasenoehrl T, Wessner B, Tschan H, Vidotto C, Crevenna R, Csapo R (2016) Eccentric resistance training intensity may affect the severity of exercise induced muscle damage. J Sports Med Phys Fitness

82.

Ahmadi H, Daneshmand S (2013) Androgen deprivation therapy: evidence-based management of side effects. BJU Int 111:543–548. doi:10.1111/j.1464-410X.2012.11774.x CrossRefPubMed

83.

Alibhai SMH, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, Krahn M, Fleshner NE, Warde P, Canning SD, Klotz L, Naglie G (2010) Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 28:5038–5045. doi:10.1200/JCO.2010.29.8091 CrossRefPubMed

Title: Effects of resistance exercise in prostate cancer patients: a meta-analysis
Authors: M. Keilani
T. Hasenoehrl
L. Baumann
R. Ristl
M. Schwarz
M. Marhold
T. Sedghi Komandj
R. Crevenna
Publication date: 01-09-2017
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 9/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3771-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2017

Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population

Impact of dyspnea on advanced cancer patients referred to a palliative radiotherapy clinic

Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma

Cardiorespiratory fitness and muscle strength in pancreatic cancer patients

Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study

Voice rehabilitation after laryngeal cancer: Associated effects on psychological well-being

Keynote webinar | Spotlight on antibody–drug conjugates in cancer